Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: A single-center inception cohort study

Clinical Rheumatology

Volumn 33, Issue 5, 2014, Pages 649-657

  Pokroy Shapira, Elisheva ^a   Gelernter, Ilana ^b   Molad, Yair ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chronic kidney disease; Hydroxychloroquine; Outcome; Renal; Survival; Systemic lupus erythematosus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DATA BASE; DEMOGRAPHY; DISEASE ACTIVITY SCORE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SLEDAI; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS; CHEMISTRY; COMPLICATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYCHLOROQUINE; KAPLAN-MEIER ESTIMATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902373841     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2527-0     Document Type: Article

References (46)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1-150
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305
3. Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D (1999) Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 56:2214-2219 (Pubitemid 30004750)
4. Sarnak MJ, Levey AS, Schoolwerth AC, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108:2154-2169 (Pubitemid 37337595)
5. Goicoechea M, de Vinuesa SG, Gómez-Campderá F, Luño J (2005) Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD). Kidney Int Suppl 93:S35-S38 (Pubitemid 40019213)
6. D'Cruz DP, Khamashta M, Hughes GR (2007) Systemic lupus erythematosus. Lancet 369:587-596 (Pubitemid 46241445)
7. Seshan SV, Jennette JC (2009) Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis. Advances and implications. Arch Pathol Lab Med 133:233-248
8. Zhang W, Agheh E, Reich HN et al (2011) Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus. Rheumatology 50:799-805
9. Croca SC, Rodrigues T, Isenberg D (2011) Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology 50:1424-1430
10. Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S (2010) Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 62:873-880
11. Baranowska-Daca E, Choi YJ, Barrios R, Nassar G, Suki WN, Truong LD (2001) Nonlupus nephritides in patients with systemic lupus erythematosus: a comprehensive clinicopathologic study and review of the literature. Hum Pathol 32:1125-1135 (Pubitemid 33015674)
12. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
13. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277 (Pubitemid 13221242)
14. Nirel N, Rosen B, Sharon A, Blondheim O, Sherf M, Samuel H, Cohen AD (2010) The impact of an integrated hospital-community medical information system on quality and service utilization in hospital departments. Int J Med Inform 79:649-657
15. Gladman DD, Ibanez D, Urowitz MB (2002) Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 29:288-291 (Pubitemid 34118775)
16. Gladman DD, Urowitz MB, Goldsmith CH et al (1997) The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 40:809-813 (Pubitemid 27199995)
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Modification of Diet in Renal Disease Study Group (1999) A more accurate method to estimate glomerular filtrating rate from serum creatinine: a new prediction equation. Ann Intern Med 130:461-470 (Pubitemid 29135798)
18. Leung YY, Lo KM, Szeto CC, Li EK, Kun EW(2006) Estimation of glomerular filtration rate in patients with systemic lupus erythematosus. Lupus 15:276-281 (Pubitemid 43828803)
19. Austin HA, Muenz LR, Joyce KM et al (1983) Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75:382-391 (Pubitemid 13005770)
20. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338-346
21. McMahon M, Hahn BH, Skaggs BJ (2011) Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol 7:227-241
22. Mok CC (2005) Prognostic factors in lupus nephritis. Lupus 14:39-44
23. Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE (1995) Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 4:109-115
24. Mok CC, Wong RW, Lau CS (1999) Lupus nephritis in southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis 34:315-323 (Pubitemid 29362098)
25. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD, Lupus Nephritis Collaborative Study Group (2000) Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 35:904-914 (Pubitemid 30238204)
26. Austin HA III, Boumpas DT, Vaughan EM, Balow JE (1995) Highrisk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10:1620-1628
27. Esdaile JM, Federgreen W, Quintal H, Suissa S, Hayslett JP, Kashgarian M (1991) Predictors of one year outcome in lupus nephritis: the importance of renal biopsy. Q J Med 81:907-918
28. Reich HN, Gladman DD, Urowitz MB et al (2011) Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. Kidney Int 79:914-920
29. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS (2007) Prevalence of chronic kidney disease in the United States. JAMA 298(17):2038-2047 (Pubitemid 350074801)
30. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, Hallan HA, Lydersen S, Holmen J (2006) International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 17(8):2275-2284 (Pubitemid 44141918)
31. Zhang L, Zhang P, Wang F, Zuo L, Zhou Y, Shi Y, Li G, Jiao S, Liu Z, Liang W, Wang H (2008) Prevalence and factors associated with CKD. Am J Kidney Dis 51(3):373-384
32. Al-Herz A, Ensworth S, Shojania K, Esdaile JM (2003) Cardiovascular risk factor screening in systemic lupus erythematosus. J Rheumatol 30:493-496 (Pubitemid 36301940)
33. Budman DR, Steinberg AD (1976) Hypertension and renal disease in systemic lupus erythematosus. Arch Intern Med 136:1003-1007
34. Ryan MJ (2009) The pathophysiology of hypertension in systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol 296:R1258-R1267
35. Molad Y, Gorshttein A, Wysenbeek AJ et al (2002) Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort. Lupus 11:356-361 (Pubitemid 34760633)
36. Esdaile J (1991) For the Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324:150-154
37. Fessler BJ, Alarcón GS, McGwin G Jr, LUMINA Study Group et al (2005) Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52:1473-1480 (Pubitemid 40663939)
38. Alarcon GS, McGwin G, Bertoli AM, LUMINA Study Group et al (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, amultiethnic US cohort (LUMINA L). Ann Rheum Dis 66:1168-1172 (Pubitemid 47309732)
39. Ruiz-Irastorza G, Khamashta MA (2008) Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 17:271-273 (Pubitemid 351655791)
40. Pons-Estel GJ, Alarcón GS, McGwin G Jr, Lumina Study Group (2009) Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis. LXV. Data from a multiethnic US cohort. Arthritis Rheum 61:830-839
41. Kasitanon N, Fine DM, Haas M, Magder LS, Peti M (2006) Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15:366-370 (Pubitemid 44032712)
42. Sisó A, Ramos-Casals M, Bové A et al (2008) Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 17:281-288 (Pubitemid 351655794)
43. Sisó A, Ramos-Casals M, Bové A et al (2010) Outcomes in biopsyproven lupus nephritis: evaluation of 190 white patients froma single center. Medicine (Baltimore) 89:300-307
44. Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R (2011) Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 186:4794-4804
45. Papadimitraki ED, Tzardi M, Bertsias G, Sotsiou E, Boumpas DT (2009) Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. Lupus 18:831-835
46. Frieri M, Samih MA, Dzhindzhikhashvili M, Liu H, Balsam L, Rubinstein S (2012) Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J Nephrol 25:1041-1046